1. Home
  2. LTRN vs COEP Comparison

LTRN vs COEP Comparison

Compare LTRN & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LTRN
  • COEP
  • Stock Information
  • Founded
  • LTRN 2013
  • COEP 2017
  • Country
  • LTRN United States
  • COEP United States
  • Employees
  • LTRN N/A
  • COEP N/A
  • Industry
  • LTRN Biotechnology: Pharmaceutical Preparations
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LTRN Health Care
  • COEP Health Care
  • Exchange
  • LTRN Nasdaq
  • COEP Nasdaq
  • Market Cap
  • LTRN 33.7M
  • COEP 32.4M
  • IPO Year
  • LTRN 2020
  • COEP N/A
  • Fundamental
  • Price
  • LTRN $4.95
  • COEP $12.48
  • Analyst Decision
  • LTRN Hold
  • COEP
  • Analyst Count
  • LTRN 1
  • COEP 0
  • Target Price
  • LTRN N/A
  • COEP N/A
  • AVG Volume (30 Days)
  • LTRN 165.9K
  • COEP 114.7K
  • Earning Date
  • LTRN 03-17-2025
  • COEP 03-25-2025
  • Dividend Yield
  • LTRN N/A
  • COEP N/A
  • EPS Growth
  • LTRN N/A
  • COEP N/A
  • EPS
  • LTRN N/A
  • COEP N/A
  • Revenue
  • LTRN N/A
  • COEP N/A
  • Revenue This Year
  • LTRN N/A
  • COEP N/A
  • Revenue Next Year
  • LTRN N/A
  • COEP N/A
  • P/E Ratio
  • LTRN N/A
  • COEP N/A
  • Revenue Growth
  • LTRN N/A
  • COEP N/A
  • 52 Week Low
  • LTRN $2.79
  • COEP $2.31
  • 52 Week High
  • LTRN $11.99
  • COEP $13.70
  • Technical
  • Relative Strength Index (RSI)
  • LTRN 55.32
  • COEP 63.07
  • Support Level
  • LTRN $4.50
  • COEP $8.65
  • Resistance Level
  • LTRN $5.70
  • COEP $12.95
  • Average True Range (ATR)
  • LTRN 0.47
  • COEP 1.62
  • MACD
  • LTRN -0.05
  • COEP -0.17
  • Stochastic Oscillator
  • LTRN 34.56
  • COEP 74.65

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: